95 related articles for article (PubMed ID: 2862613)
1. Immunoreactive somatostatin-28(1-12) is increased in Huntington's disease.
Beal MF; Benoit R; Bird ED; Martin JB
Neurosci Lett; 1985 May; 56(3):377-80. PubMed ID: 2862613
[TBL] [Abstract][Full Text] [Related]
2. Reduced density of striatal somatostatin receptors in Huntington's chorea.
Palacios JM; Rigo M; Chinaglia G; Probst A
Brain Res; 1990 Jul; 522(2):342-6. PubMed ID: 1977497
[TBL] [Abstract][Full Text] [Related]
3. Excitotoxin lesions do not mimic the alteration of somatostatin in Huntington's disease.
Beal MF; Marshall PE; Burd GD; Landis DM; Martin JB
Brain Res; 1985 Dec; 361(1-2):135-45. PubMed ID: 2867808
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington's disease.
Beal MF; Mazurek MF; Ellison DW; Swartz KJ; McGarvey U; Bird ED; Martin JB
Ann Neurol; 1988 Jun; 23(6):562-9. PubMed ID: 2900622
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin is increased in the nucleus accumbens in Huntington's disease.
Beal MF; Bird ED; Langlais PJ; Martin JB
Neurology; 1984 May; 34(5):663-6. PubMed ID: 6143284
[TBL] [Abstract][Full Text] [Related]
6. Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease.
De Souza EB; Whitehouse PJ; Folstein SE; Price DL; Vale WW
Brain Res; 1987 Dec; 437(2):355-9. PubMed ID: 2893655
[TBL] [Abstract][Full Text] [Related]
7. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease.
Dawbarn D; De Quidt ME; Emson PC
Brain Res; 1985 Aug; 340(2):251-60. PubMed ID: 2862959
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin is increased in the basal ganglia in Huntington disease.
Aronin N; Cooper PE; Lorenz LJ; Bird ED; Sagar SM; Leeman SE; Martin JB
Ann Neurol; 1983 May; 13(5):519-26. PubMed ID: 6191621
[TBL] [Abstract][Full Text] [Related]
9. Huntington's disease is accompanied by changes in the distribution of somatostatin-containing neuronal processes.
Marshall PE; Landis DM
Brain Res; 1985 Mar; 329(1-2):71-82. PubMed ID: 2858256
[TBL] [Abstract][Full Text] [Related]
10. Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease.
Pearson SJ; Reynolds GP
Neurosci Lett; 1992 Sep; 144(1-2):199-201. PubMed ID: 1436703
[TBL] [Abstract][Full Text] [Related]
11. Regional somatostatin distribution in the rat striatum.
Beal MF; Domesick VB; Martin JB
Brain Res; 1983 Nov; 278(1-2):103-8. PubMed ID: 6139149
[TBL] [Abstract][Full Text] [Related]
12. Elevation of Met-enkephalin-like immunoreactivity in the rat striatum and globus pallidus following the focal injection of excitotoxins.
Ruzicka BB; Jhamandas K
Brain Res; 1990 Dec; 536(1-2):227-39. PubMed ID: 2150770
[TBL] [Abstract][Full Text] [Related]
13. A survey of substance P, somatostatin, and neurotensin levels in aging in the rat and human central nervous system.
Buck SH; Deshmukh PP; Burks TF; Yamamura HI
Neurobiol Aging; 1981; 2(4):257-64. PubMed ID: 6174878
[TBL] [Abstract][Full Text] [Related]
14. HPLC analysis of somatostatin related peptides in putamen of Huntington's disease patients.
Sperk G; Reynolds GP; Riederer P
J Neural Transm; 1987; 69(1-2):153-60. PubMed ID: 2953863
[TBL] [Abstract][Full Text] [Related]
15. Immunocytochemical studies of substance P and leucine-enkephalin in Huntington's disease.
Marshall PE; Landis DM; Zalneraitis EL
Brain Res; 1983 Dec; 289(1-2):11-26. PubMed ID: 6198034
[TBL] [Abstract][Full Text] [Related]
16. Demonstration and nature of endothelin-3-like immunoreactivity in somatostatin and choline acetyltransferase-immunoreactive nerve cells of the neostriatum of the rat.
Fuxe K; Tinner B; Staines W; Hemsén A; Hersh L; Lundberg JM
Neurosci Lett; 1991 Feb; 123(1):107-11. PubMed ID: 1676496
[TBL] [Abstract][Full Text] [Related]
17. Huntington's disease: effect of cysteamine, a somatostatin-depleting agent.
Shults C; Steardo L; Barone P; Mohr E; Juncos J; Serrati C; Fedio P; Tamminga CA; Chase TN
Neurology; 1986 Aug; 36(8):1099-102. PubMed ID: 2874527
[TBL] [Abstract][Full Text] [Related]
18. Opioid peptides in Huntington's disease: alterations in prodynorphin and proenkephalin system.
Seizinger BR; Liebisch DC; Kish SJ; Arendt RM; Hornykiewicz O; Herz A
Brain Res; 1986 Jul; 378(2):405-8. PubMed ID: 2873872
[TBL] [Abstract][Full Text] [Related]
19. Reduced somatostatin-like immunoreactivity in the brain of LEC rats with hepatic encephalopathy.
Tateishi K; Miura Y; Moriai O; Suzuki K; Takeichi N; Kobayashi H; Matsuoka Y; Sato S
Regul Pept; 1991 Oct; 36(1):131-9. PubMed ID: 1686662
[TBL] [Abstract][Full Text] [Related]
20. Cortical peptide changes in Huntington's disease may be independent of striatal degeneration.
Mazurek MF; Garside S; Beal MF
Ann Neurol; 1997 Apr; 41(4):540-7. PubMed ID: 9124812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
